Overview
Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia. It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors. Prochlorperazine was first developed in the 1950s and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.
Indication
主要用于精神障碍，亦用于治疗严重的恶心、呕吐。
Associated Conditions
- Acute Migraine
- Schizophrenia
- Tension Headache
- Non-psychotic generalized anxiety
- Severe Nausea and vomiting
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/06/10 | Phase 2 | Recruiting | |||
2024/03/15 | Phase 4 | Completed | |||
2023/12/26 | Not Applicable | Recruiting | |||
2023/10/16 | Phase 2 | Recruiting | |||
2023/08/01 | Phase 3 | Completed | |||
2021/08/19 | Early Phase 1 | Withdrawn | Koen van Besien | ||
2020/08/07 | Phase 3 | Terminated | |||
2019/10/01 | Phase 2 | Terminated | Christian Fromm, MD | ||
2019/06/12 | Phase 3 | UNKNOWN | |||
2018/02/15 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Rebel Distributors Corp | 21695-571 | ORAL | 5 mg in 1 1 | 6/11/2010 | |
| Blenheim Pharmacal, Inc. | 10544-511 | ORAL | 5 mg in 1 1 | 2/25/2015 | |
| ANI Pharmaceuticals, Inc. | 70954-688 | ORAL | 5 mg in 1 1 | 1/9/2024 | |
| FOSUN PHARMA USA INC | 72266-204 | INTRAVENOUS, INTRAMUSCULAR | 5 mg in 1 mL | 5/4/2023 | |
| Liberty Pharmaceuticals, Inc. | 0440-8190 | ORAL | 5 mg in 1 1 | 9/11/2013 | |
| Bryant Ranch Prepack | 72162-2262 | ORAL | 10 mg in 1 1 | 2/18/2019 | |
| PD-Rx Pharmaceuticals, Inc. | 55289-119 | RECTAL | 25 mg in 1 1 | 3/11/2024 | |
| PharmPak, Inc. | 54348-114 | ORAL | 10 mg in 1 1 | 10/8/2022 | |
| Cardinal Health 107, LLC | 55154-4183 | INTRAMUSCULAR, INTRAVENOUS | 5 mg in 1 mL | 12/21/2018 | |
| Hikma Pharmaceuticals USA Inc. | 0641-6225 | INTRAMUSCULAR, INTRAVENOUS | 5 mg in 1 mL | 4/3/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| STEMETIL INJECTION 12.5 mg/ml | SIN01382P | INJECTION | 12.5 mg/ml | 5/19/1988 | |
| PROCHLOR TABLETS 5 mg | SIN02049P | TABLET | 5 mg | 6/23/1988 | |
| PROPERAZINE TABLET 5 mg | SIN03002P | TABLET | 5 mg | 5/31/1989 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Perphenazine Injection | 国药准字H31021085 | 化学药品 | 注射剂 | 10/9/2020 | |
| Perphenazine Injection | 国药准字H12020988 | 化学药品 | 注射剂 | 7/27/2020 | |
| Perphenazine Injection | 国药准字H37022064 | 化学药品 | 注射剂 | 3/25/2020 | |
| Perphenazine Injection | 国药准字H11020929 | 化学药品 | 注射剂（小容量注射剂） | 8/11/2021 | |
| Perphenazine Tablets | 国药准字H32023122 | 化学药品 | 片剂 | 6/23/2020 | |
| Perphenazine Tablets | 国药准字H37022065 | 化学药品 | 片剂 | 3/12/2020 | |
| Perphenazine Tablets | 国药准字H21022857 | 化学药品 | 片剂 | 5/12/2020 | |
| Perphenazine Tablets | 国药准字H32023757 | 化学药品 | 片剂 | 7/22/2020 | |
| Perphenazine Tablets | 国药准字H21020417 | 化学药品 | 片剂 | 7/23/2020 | |
| Perphenazine Tablets | 国药准字H23022326 | 化学药品 | 片剂（糖衣） | 2/11/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| PROCHLORPERAZINE MALEATE TABLETS 5MG | N/A | N/A | N/A | 8/2/2018 |
TGA Drug Approvals
Help Us Improve
Your feedback helps us provide better drug information and insights.